ConAgra Brands (CAG) Tops Q2 EPS by 2c, Guidance Misses Consensus

ConAgra Brands (NYSE: CAG) reported Q2 EPS of $0.70, $0.02 better than the analyst estimate of $0.68. Revenue for the quarter came in at $3.2 billion versus the consensus estimate of $3.15 billion.

GUIDANCE:

ConAgra Brands sees FY2025 EPS of $2.45-$2.50, versus the consensus of $2.58.

• Organic net sales near the midpoint of (1.5)% to flat compared to fiscal 2024
• Adjusted operating margin of approximately 14.8%
• Adjusted EPS between $2.45 and $2.50
• Free cash flow conversion of greater than 100%

For earnings history and earnings-related data on ConAgra Brands (CAG) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Stardust Power (SDST) Tops Q2 EPS by 1c